Concepedia

Ralf Spitthöver

RS

Statistics

Publications

6

Citations

123

H-Index

6

Active since

2001

Affiliations

Max Planck Institute for Metabolism Research(Current)

PHV Dialysezentrum

West German Heart and Vascular Center Essen

Essen University Hospital

Genesis Research Institute

Ralf Spitthöver is an author at Max Planck Institute for Metabolism Research specializing in dyslipidemia management, lipid-lowering therapy, and low-density lipoprotein cholesterol lowering.

Publications per year

2001–2020

6

Publications

6

The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine

Heike Bruck, Mario Gössl, Ralf Spitthöver et al. · Journal of Hypertension · 2001 · 34 citations

, , +14

Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis

Christina Taylan, Joenna Driemeyer, Claus Peter Schmitt et al. · The American Journal of Cardiology · 2020 · 23 citations

, , +16

Relapsing and Progressive Complications of Severe Hypertriglyceridemia: Effective Long-Term Treatment with Double Filtration Plasmapheresis

Clemens Grupp, J. Beckermann, Eric Köster et al. · Blood Purification · 2020 · 22 citations · Full text

, , +11

Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia—target attainment requires further increase of intensity

Günter Klaus, Christina Taylan, Rainer Büscher et al. · Pediatric Nephrology · 2018 · 15 citations

, , +16

Real‐world study: Escalating targeted lipid‐lowering treatment with PCSK9‐inhibitors and lipoprotein apheresis

Ralf Spitthöver, Tilmann Röseler, Ulrich Julius et al. · Journal of Clinical Apheresis · 2019 · 15 citations · Full text

, , +16

1–5 of 6